Biodesix (BDSX)

Executive Summary

Biodesix, Inc. (NASDAQ: BDSX) is a precision diagnostics company specializing in blood-based tests for lung disease, particularly lung cancer. Its commercial portfolio includes the Nodify Lung® nodule risk assessment tests and the GeneStrat® targeted mutation test, which guide treatment decisions. The company also has a pipeline of therapeutic candidates, though recent trials have been withdrawn or terminated. Biodesix's strategy focuses on integrating diagnostic data into clinical decision-making, with a growing emphasis on multi-omics approaches. Financially, the company has a market cap of approximately $152 million and has completed five funding rounds. The stock is estimated to be valued sub-$200 million, reflecting the competitive diagnostics market and the need for clear revenue growth catalysts. Despite a challenging landscape, Biodesix's FDA-cleared tests provide a foundation for near-term commercial expansion.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance of New Liquid Biopsy Test for Lung Cancer60% success
• Q4 2026Partnership with Major Pharma for Companion Diagnostic Co-Development50% success
• Q1 2027Positive Medicare Coverage Decision for Nodify Lung Tests70% success